Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Step Aside, Novo Nordisk. This Is Europe’s No. 1 Company Now.
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
STAT10h
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Le Lézard15h
MUHC Foundation Receives $2 million Donation to establish the MUHC's Metabolic Centre of Excellence
Foundation is proud to announce a $2 million donation from Novo Nordisk Canada Inc. to support the establishment of the Metabolic Centre of Excellence at the MUHC. This contribution will help position ...
New Atlas22h
Next-gen weight-loss drugs will be here within 12 months
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
SAP has just become Europe's most valuable company, dethroning Novo Nordisk
The German software company's share price gained 40% in the past year, while Danish drugmaker Novo Nordisk has gradually lost ...
Novo licenses Chinese biotech's obesity drug candidate for up to $2 billion
As part of the agreement with a United Lab unit announced on Monday, Novo will make an upfront payment of $200 million and up to $1.8 billion upon the completion of certain development and sales ...